These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20621541)

  • 21. LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.
    Bardien S; Marsberg A; Keyser R; Lombard D; Lesage S; Brice A; Carr J
    J Neural Transm (Vienna); 2010 Jul; 117(7):847-53. PubMed ID: 20544233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.
    Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V
    Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.
    Bar-Shira A; Hutter CM; Giladi N; Zabetian CP; Orr-Urtreger A
    Neurogenetics; 2009 Oct; 10(4):355-8. PubMed ID: 19283415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LRRK2 R1441G in Spanish patients with Parkinson's disease.
    Mata IF; Taylor JP; Kachergus J; Hulihan M; Huerta C; Lahoz C; Blazquez M; Guisasola LM; Salvador C; Ribacoba R; Martinez C; Farrer M; Alvarez V
    Neurosci Lett; 2005 Jul; 382(3):309-11. PubMed ID: 15925109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
    Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans.
    Lesage S; Patin E; Condroyer C; Leutenegger AL; Lohmann E; Giladi N; Bar-Shira A; Belarbi S; Hecham N; Pollak P; Ouvrard-Hernandez AM; Bardien S; Carr J; Benhassine T; Tomiyama H; Pirkevi C; Hamadouche T; Cazeneuve C; Basak AN; Hattori N; Dürr A; Tazir M; Orr-Urtreger A; Quintana-Murci L; Brice A;
    Hum Mol Genet; 2010 May; 19(10):1998-2004. PubMed ID: 20197411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
    Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
    Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
    Tomiyama H; Li Y; Funayama M; Hasegawa K; Yoshino H; Kubo S; Sato K; Hattori T; Lu CS; Inzelberg R; Djaldetti R; Melamed E; Amouri R; Gouider-Khouja N; Hentati F; Hatano Y; Wang M; Imamichi Y; Mizoguchi K; Miyajima H; Obata F; Toda T; Farrer MJ; Mizuno Y; Hattori N
    Mov Disord; 2006 Aug; 21(8):1102-8. PubMed ID: 16622854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
    Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
    Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease.
    Funalot B; Nichols WC; Pérez-Tur J; Mercier G; Lucotte G
    Genet Test; 2006; 10(4):290-3. PubMed ID: 17253937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
    Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
    J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.
    Goldwurm S; Di Fonzo A; Simons EJ; Rohé CF; Zini M; Canesi M; Tesei S; Zecchinelli A; Antonini A; Mariani C; Meucci N; Sacilotto G; Sironi F; Salani G; Ferreira J; Chien HF; Fabrizio E; Vanacore N; Dalla Libera A; Stocchi F; Diroma C; Lamberti P; Sampaio C; Meco G; Barbosa E; Bertoli-Avella AM; Breedveld GJ; Oostra BA; Pezzoli G; Bonifati V
    J Med Genet; 2005 Nov; 42(11):e65. PubMed ID: 16272257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian.
    Carmine Belin A; Westerlund M; Sydow O; Lundströmer K; Håkansson A; Nissbrandt H; Olson L; Galter D
    Mov Disord; 2006 Oct; 21(10):1731-4. PubMed ID: 16817197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
    Hatano T; Funayama M; Kubo SI; Mata IF; Oji Y; Mori A; Zabetian CP; Waldherr SM; Yoshino H; Oyama G; Shimo Y; Fujimoto KI; Oshima H; Kunii Y; Yabe H; Mizuno Y; Hattori N
    Neurobiol Aging; 2014 Nov; 35(11):2656.e17-2656.e23. PubMed ID: 24973808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease.
    Marongiu R; Ghezzi D; Ialongo T; Soleti F; Elia A; Cavone S; Albanese A; Altavista MC; Barone P; Brusa L; Cortelli P; Petrozzi L; Scaglione C; Stanzione P; Tinazzi M; Zeviani M; Dallapiccola B; Bentivoglio AR; Valente EM; Garavaglia B;
    Mov Disord; 2006 Aug; 21(8):1232-5. PubMed ID: 16622859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
    Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2 G2019S founder haplotype in the Chinese population.
    Tan EK; Skipper L; Tan L; Liu JJ
    Mov Disord; 2007 Jan; 22(1):105-7. PubMed ID: 17083102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.